Abstract Number: 672 • 2019 ACR/ARP Annual Meeting
Mouse SLE Studies Do Not Describe Human SLE
Background/Purpose: Although mouse models of systemic lupus erythematosus (SLE) are useful proxies for human illness, they are heterogeneous, and publications about mouse SLE may not…Abstract Number: 1024 • 2019 ACR/ARP Annual Meeting
Lysosome Defects in SLE Promote the Accumulation of Nuclear Antigens on the Surface of Hematopoietic Cells
Background/Purpose: Impaired clearance of cell debris allows nuclear self-antigens such as DNA to accumulate, bind autoreactive IgG and form immune complexes (IgG-ICs) in SLE. We…Abstract Number: 1579 • 2019 ACR/ARP Annual Meeting
Presence of Antiphospholipid Antibodies in Patients with SLE and Venous Thromboembolic Events of African American and Caucasian Race
Background/Purpose: Risk of thrombosis is elevated in patients with systemic lupus erythematosus (SLE) compared to healthy individuals, especially during the first year after diagnosis. The…Abstract Number: 2034 • 2019 ACR/ARP Annual Meeting
Identification of IL-17+ and IL-10+ TCRαβ+ CD4- CD8- Double Negative (DN) T Cell Subsets in Lupus-prone Mice and Patients with SLE and Their Significance in Predicting Renal Involvement
Background/Purpose: We have previously shown that DN T cells are expanded in both lupus-prone mice and patients with SLE and we have demonstrated that this…Abstract Number: 64 • 2019 ACR/ARP Annual Meeting
Rab4A Controls mTOR Pathway Activation, Pro-inflammatory Lineage Development, and Disease Pathogenesis in Lupus-prone Mice
Background/Purpose: Mouse models of SLE have been indispensable tools for studying disease pathogenesis; however, each model only recapitulates limited aspects of lupus. SLE1.2.3. (TC) mice…Abstract Number: 673 • 2019 ACR/ARP Annual Meeting
Clinical Characteristics of Lymphadenopathy in Systemic Lupus Erythematous: A Case Control Study from a Tertiary Care Center
Background/Purpose: While lymphadenopathy and/or lymphadenitis (LAD) is considered a relatively common clinical finding in SLE patients, its clinical significance is poorly understood. Previous studies described…Abstract Number: 1025 • 2019 ACR/ARP Annual Meeting
Dynamic Changes During SLE Flare Implicate Age-Associated B Cells and Altered T Follicular and Peripheral Helper Cell Responses in Disease Activity
Background/Purpose: SLE is a chronic autoimmune disorder in which periods of relative disease inactivity are punctuated by flares that present with increased inflammation and tissue…Abstract Number: 1586 • 2019 ACR/ARP Annual Meeting
All-cause Hospitalizations and Mortality in Systemic Lupus Erythematosus in the US- results from a National Inpatient Database
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic multisystem autoimmune disorder with variable presentation. While several studies have outlined the risk factors for hospitalization and…Abstract Number: 2036 • 2019 ACR/ARP Annual Meeting
Mitochondrial DNA: A Potential Trigger of Cyclic GMP-AMP Synthase Activation in Systemic Lupus Erythematosus
Background/Purpose: Approximately 70% of patients with Systemic Lupus Erythematosus (SLE) show a striking Type I Interferon (IFN-I) signature in peripheral blood. Although we have some…Abstract Number: 65 • 2019 ACR/ARP Annual Meeting
CD6 Modulation Ameliorates Skin and Kidney Disease in a Spontaneous Murine Model of SLE
Background/Purpose: T cells are an important contributor the pathogenesis of SLE and its various end organ manifestations. Thus, they present themselves as potential therapeutic targets;…Abstract Number: 678 • 2019 ACR/ARP Annual Meeting
Performance of the EULAR/ACR 2019 Classification Criteria for Systemic Lupus Erythematosus in Men, Diverse Ethnicities, and Early Disease
Background/Purpose: The EULAR/ACR 2019 Classification Criteria for SLE have been validated in an international cohort of 696 SLE patients and 574 non-SLE patients with a…Abstract Number: 1033 • 2019 ACR/ARP Annual Meeting
Mass Cytometric Immunophenotyping Highlights a Dysregulated T cell-B Cell Axis in Patients with New-onset Lupus
Background/Purpose: The immune cell subsets most altered early in SLE disease course remain unclear. Defining abnormalities in lymphocyte populations in patients with new-onset SLE may…Abstract Number: 1591 • 2019 ACR/ARP Annual Meeting
Anti-ovarian Antibodies Are Not Associated with Premature Menopause in SLE Treated with Cyclophophosphamide
Background/Purpose: Treatment of systemic lupus erythematosus (SLE) with cyclophosphamide is associated with premature menopause, especially those at an older age of treatment and those receiving…Abstract Number: 2041 • 2019 ACR/ARP Annual Meeting
Epigenome-wide Association Study Reveals Differential DNA Methylation in Systemic Lupus Erythematosus Patients with a History of Ischemic Heart Disease
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have an increased risk of ischemic heart disease (IHD). Altered methylation patterns have been reported both in SLE,…Abstract Number: 66 • 2019 ACR/ARP Annual Meeting
Amelioration of Immune Complex-Mediated Glomerulonephritis by CD6 Modulation
Background/Purpose: CD6 is a co-stimulatory receptor on T cells, that binds to activated leukocyte cell adhesion molecule (ALCAM), a ligand expressed on antigen presentation cells…
- 1
- 2
- 3
- …
- 38
- Next Page »